WO2000035443A1 - Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin - Google Patents

Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin Download PDF

Info

Publication number
WO2000035443A1
WO2000035443A1 PCT/US1999/029478 US9929478W WO0035443A1 WO 2000035443 A1 WO2000035443 A1 WO 2000035443A1 US 9929478 W US9929478 W US 9929478W WO 0035443 A1 WO0035443 A1 WO 0035443A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
polyunsaturated fatty
gut
formulation
polyunsaturated
Prior art date
Application number
PCT/US1999/029478
Other languages
English (en)
Other versions
WO2000035443A9 (fr
Inventor
Susan Marie Kaup
Michael Scott Caplan
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020017007472A priority Critical patent/KR20020002361A/ko
Priority to CA002351469A priority patent/CA2351469A1/fr
Priority to JP2000587763A priority patent/JP2002532420A/ja
Priority to AU31196/00A priority patent/AU3119600A/en
Priority to BR9916156-7A priority patent/BR9916156A/pt
Priority to IL14332299A priority patent/IL143322A0/xx
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Priority to EA200100662A priority patent/EA200100662A1/ru
Priority to HU0104760A priority patent/HUP0104760A2/hu
Priority to EP99965234A priority patent/EP1140063A1/fr
Publication of WO2000035443A1 publication Critical patent/WO2000035443A1/fr
Publication of WO2000035443A9 publication Critical patent/WO2000035443A9/fr
Priority to NO20012947A priority patent/NO20012947L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C11/00—Milk substitutes, e.g. coffee whitener compositions
    • A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
    • A23C11/04—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing non-milk fats but no non-milk proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention is directed to enteral formulations that contain long- chain polyunsaturated fatty acids (PUFAs) and to methods for maintaining gut integrity and enhancing the restitution of gut integrity. More specifically the present invention is directed to formulations and methods for reducing gut permeability and restoring damaged intestinal cells to maintain and enhance the restitution of gut integrity.
  • PUFAs long- chain polyunsaturated fatty acids
  • U.S. Patent No. 4,670,285 discloses a specific fat blend suitable for use in infant formulations.
  • the fat blend contains at least one C 20 or C 22 n-6 fatty acid and one C 20 or C 22 n-3 fatty acid.
  • the C 20 or C 22 n-6 fatty acid is present in a total amount of about 0.13 to 5.6% by weight of all fatty acids in the composition.
  • the C 20 or C 22 n-3 fatty acid is included in a total amount of about 0.013 to about 4.44% by weight of all fatty acids in the composition.
  • This patent discloses the use of egg lipids to supply the fatty acids.
  • U.S. Patent No. 4,918,063 discloses formulations containing mixtures of phospholipids and neutral lipids for the prevention or treatment of ulcers and inflammatory bowel disease.
  • This patent discloses a mixture of saturated or unsaturated phospholipids, together with saturated or unsaturated triglycerides and/or sterols as providing ulcer protection in experimental animal models.
  • PCT International Publication No. WO96/10922 discloses a fat mixture for infant formula characterized in that arachadonic acid and docosahexanoic acid are present in the form of phospholipids.
  • European Patent Application No. 0376628 Bl discloses an all vegetable oil fat blend which utilizes randomized palm oil or randomized palm olein oil as the sole palmitic acid oil source. It is disclosed that the compositions are particularly useful in infant formulas particularly for preterm or low birth weight infants.
  • the present invention is directed to methods for maintaining gut integrity and enhancing the restitution of gut integrity in an individual in need thereof, comprising administering to the individual a formulation comprising at least one n-6 polyunsaturated fatty acid in combination with at least one n-3 polyunsaturated fatty acid, to formulations for use in the method comprising an effective amount of at least one n-6 polyunsaturated fatty acid in combination with at least one n-3 polyunsaturated fatty acid, and the to use of an effective amount of at least one n-6 polyunsaturated fatty acid in combination with at least one n-3 polyunsaturated fatty acid in the manufacture of a medicament for use in maintaining gut integrity and enhancing the restitution of gut integrity in an individual in need thereof.
  • Figure 1 compares plasma endotoxin levels in rats supplemented with the formulation of the invention to rats that have not been supplemented.
  • Figure 2 shows the effect of the present formulation on intestinal PLA 2 mRNA expression levels.
  • Figure 3 shows the effect of the present formula on intestinal PAF-receptor levels in RNA.
  • the polyunsaturated fatty acids useful in the present invention include fatty acids of twenty carbons or more having at least two carbon-carbon double bonds.
  • the number and position of double bonds in the fatty acids are designated by the nomenclature conventionally used.
  • arachidonic acid has a chain length of 20 carbon atoms and 4 double bonds beginning at the sixth carbon from the end of the molecule. Accordingly, arachidonic acid is referred to as C 20 :4 n-6.
  • docosahexanoic acid has a chain length of 22 carbon atoms with 6 double bonds beginning at the third carbon from the end of the molecule and is designated C 22 :6 n-3.
  • the n-6 polyunsaturated fatty acid used in the present invention is arachidonic acid and the n-3 polyunsaturated fatty acid used in the present invention is docosahexanoic acid.
  • the method of the present invention comprises administering to an individual having one or more disorders characterized by cell damage or destruction to gut tissue an effective amount of a formulation containing at least one n-6 polyunsaturated fatty acid and at least one n-3 polyunsaturated fatty acid. Effective amounts of the n-6 polyunsaturated fatty acid is about 5 to 61 mg and preferably 10 to 51 mg/kg body weight.
  • effective amounts of the n-3 polyunsaturated fatty acid is about 5 to 61 and preferably 5 to 51 mg/kg body weight.
  • the effective arachidonic acid: docosahexanoic acid ratio is about 1: 1 to 2.5:1, and preferably 1 :1 to 2:1. This is based on administration of 100 kcal/kg/day for a 1 kg infant.
  • the formulations used in the present method should comprise about 4 to about 50, and preferably about 8 to about 41 mg/100 ml of polyunsaturated fatty acid.
  • the formulations used in the present method should comprise about 4 to about 50, and preferably about 4 to about 41 mg/100 ml of the n-3 polyunsaturated fatty acid.
  • the effective arachidonic acid: docosahexanoic acid ratio is 1:1 to 2.5: 1 and preferably 1 : 1 to 2: 1.
  • the present invention is directed to methods for maintaining gut integrity and enhancing the restitution of gut integrity, to formulations for use in for maintaining gut integrity and enhancing the restitution of gut integrity and to the use of an effective amount at least one n-6 polyunsaturated fatty acid in combination with at least one n-3 polyunsaturated fatty acid in the manufacture of a medicament for use in for maintaining gut integrity and enhancing the restitution of gut integrity.
  • Gut integrity is compromised in a number of disease states which increase gut permeability, cause cell damage or destruction in the gut and cause bacterial translocation in the gut which may lead to endotoxemia.
  • a preferred embodiment of this invention is a method or formulation for maintaining and enhancing the restitution of gut integrity in infants, particularly preterm infants. This method comprises enterally administering to the infants a nutritionally complete infant formula comprising proteins, carbohydrates, lipids and effective amounts of at least one n-6 polyunsaturated fatty acid and at least one n-3 polyunsaturated fatty acid.
  • n-6 and n-3 polyunsaturated fatty acid examples include S-26, S-26 LBW and SMA available from Wyeth Nutritionals International.
  • Fat Blend 1 Specific examples of fat blends containing appropriate amounts of n-6 and n-3 polyunsaturated fatty acids according to the present invention are set forth below: Fat Blend 1
  • the method of the present invention was tested in a neonatal rat model of hypoxia induced gut injury. Reduced gut permeability is associated with reduced endotoxemia and a lowered intestinal phospholipase-2 (PLA 2 ) gene expression.
  • PHA 2 intestinal phospholipase-2
  • Rat pups were delivered via abdominal incision from time- dated pregnant Sprague-Dawley rats on the 21st day of gestation.
  • the newborn rats were fed via the orogastric route 0.1 ml of formula (S26-LBW formula, available from Wyeth Nutritionals International, Burlington, VT) every three hours with the volume advanced as tolerated up to 0.4 ml by 72 hours of life.
  • animals were stressed with asphyxia twice daily by breathing 100% nitrogen gas for 5.0 seconds and then cold exposure to 4°C for 10 minutes. Using this protocol, 70-80% of animals develop abdominal necrosis by the 3rd to 4th day of life as described in
  • Treatment Groups There were 2 treatment groups: preterm formula
  • LCPUFAs added to Formula B were arachidonic acid and docosahexanoic acid.
  • the LCPUFAs were added in the following amounts: 20 mg/lOOkcal docosahexanoic acid and 30 mg/100 kcal arachidonic acid.
  • the first component of the study examined gut damage which was confirmed at time of necropsy by gross examination and histopathology. Gross examination and histopathology characterized changes in gut damage, maturity and integrity.
  • the second component of the study investigated the mechanisms underlying changes in gut damage, maturity and integrity. The following outcome variables were measured: endotoxemia and PLA 2 .
  • Plasma endotoxin was assessed using a spectrophotometric method provided in a Limulus Amebocyte Lysate (LAL) assay commercially available from Biowhittaker, Walkersville, MD.
  • LAL Limulus Amebocyte Lysate
  • Phospholipase A mRNA expression.
  • PLA Limulus Amebocyte Lysate
  • Animals developed symptoms of intestinal injury typically between 48 and 72 hours of life, and included abdominal distention, discoloration of the anterior abdominal wall, bloody stools, and respiratory distress.
  • LCPUFA supplementation reduces gut injury in an established neonatal rat model of ischemic gut damage. Furthermore, the data demonstrate that the beneficial effect of LCPUFA supplementation includes reduced gut permeability.
  • the reduced gut permeability was associated with a reduction in endotoxemia. Endotoxemia is a result of bacterial and/or endotoxin translocation across the gut into the systemic circulation. Concurrent lower expressions of intestinal PLA 2 mRNA and PAF receptor mRNA were indicative of a reduced endotoxin induced inflammatory response.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pediatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne un procédé, ainsi qu'une formulation à utiliser dans le procédé, permettant d'entretenir et de renforcer la restitution de l'intégrité de l'intestin chez un individu qui en a besoin. Le procédé consiste à administrer à l'individu une formulation comprenant une dose efficace d'au moins un acide gras n-6 polyinsaturé combiné avec au moins un acide gras n-3 polyinsaturé.
PCT/US1999/029478 1998-12-15 1999-12-13 Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin WO2000035443A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002351469A CA2351469A1 (fr) 1998-12-15 1999-12-13 Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin
JP2000587763A JP2002532420A (ja) 1998-12-15 1999-12-13 腸管完全性の維持および回復のための方法および組成物
AU31196/00A AU3119600A (en) 1998-12-15 1999-12-13 Method and composition for the maintenance and restitution of gut integrity
BR9916156-7A BR9916156A (pt) 1998-12-15 1999-12-13 Método e composição para a manutenção e restituição de integridade do intestino
IL14332299A IL143322A0 (en) 1998-12-15 1999-12-13 Method and composition for the maintenance and restitution of gut integrity
KR1020017007472A KR20020002361A (ko) 1998-12-15 1999-12-13 소화관 통합성의 유지 및 회복 방법 및 이를 위한 조성물
EA200100662A EA200100662A1 (ru) 1998-12-15 1999-12-13 Способ и композиция для поддержания и восстановления целостности кишки
HU0104760A HUP0104760A2 (hu) 1998-12-15 1999-12-13 Eljárás és készítmény a bél épségének megtartására és helyreállítására
EP99965234A EP1140063A1 (fr) 1998-12-15 1999-12-13 Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin
NO20012947A NO20012947L (no) 1998-12-15 2001-06-14 Fremgangsmåte og blanding for opprettholdelse og restituering av tarmintegritet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11237498P 1998-12-15 1998-12-15
US60/112,374 1998-12-15

Publications (2)

Publication Number Publication Date
WO2000035443A1 true WO2000035443A1 (fr) 2000-06-22
WO2000035443A9 WO2000035443A9 (fr) 2000-12-07

Family

ID=22343574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029478 WO2000035443A1 (fr) 1998-12-15 1999-12-13 Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin

Country Status (14)

Country Link
EP (1) EP1140063A1 (fr)
JP (1) JP2002532420A (fr)
KR (1) KR20020002361A (fr)
CN (1) CN1330542A (fr)
AR (1) AR021669A1 (fr)
AU (1) AU3119600A (fr)
BR (1) BR9916156A (fr)
CA (1) CA2351469A1 (fr)
EA (1) EA200100662A1 (fr)
HU (1) HUP0104760A2 (fr)
IL (1) IL143322A0 (fr)
NO (1) NO20012947L (fr)
PL (1) PL348810A1 (fr)
WO (1) WO2000035443A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112509A2 (fr) * 2003-06-23 2004-12-29 Nestec S.A. Formule nutritionnelle pour fonction de barriere intestinale optimale
WO2006113034A1 (fr) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Utilisation de lactobacillus rhamnosus gg en combinaison avec un acide gras polyinsature a chaine longue pour traiter, prevenir ou attenuer une inflammation systemique chez un nourrisson nourri au lait maternise
US7837989B2 (en) 2005-04-15 2010-11-23 Mead Johnson Nutrition Company Method for preventing or treating the development of respiratory allergies
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
WO2016050752A1 (fr) * 2014-09-30 2016-04-07 Nestec S.A. Composition nutritionnelle destinée à être utilisée pour activer la maturation et/ou la réparation des intestins et/ou du foie
US9844517B2 (en) 2010-12-29 2017-12-19 Abbott Laboratories Nutritional products including a novel fat system including fatty acids

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
WO2023245470A1 (fr) * 2022-06-22 2023-12-28 南方医科大学珠江医院 Utilisation d'un analogue de mdp dans la préparation d'un médicament pour le traitement d'une maladie intestinale inflammatoire

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
EP0231904A2 (fr) * 1986-01-31 1987-08-12 MILUPA GmbH & Co. KG Mélange gras riche en acides polyéniques et son utilisation dans la préparation d'aliments pour nourrissons
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
EP0682879A1 (fr) * 1994-05-20 1995-11-22 HEIRLER, Horst Aliments diététiques avec acides gras à chaîne moyenne et leur application
EP0711503A2 (fr) * 1994-11-14 1996-05-15 Scotia Holdings Plc Lait fortifié avec GLA et/ou DGLA
EP0733360A2 (fr) * 1992-11-26 1996-09-25 Scotia Holdings Plc Utilisation d'une composition d'acides arachidoniques et docosahexaénoiques pour la fabrication d'un médicament pour le traitement d'abnormalités de membranes cellulaires à cause d'acides gras essentiels C20 et C22 diminués
WO1998048646A2 (fr) * 1997-05-01 1998-11-05 Beth Israel Deaconess Medical Center Inc. Formulation alimentaire contenant de l'acide arachidonique et procede d'utilisation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670285A (en) * 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
EP0231904A2 (fr) * 1986-01-31 1987-08-12 MILUPA GmbH & Co. KG Mélange gras riche en acides polyéniques et son utilisation dans la préparation d'aliments pour nourrissons
EP0733360A2 (fr) * 1992-11-26 1996-09-25 Scotia Holdings Plc Utilisation d'une composition d'acides arachidoniques et docosahexaénoiques pour la fabrication d'un médicament pour le traitement d'abnormalités de membranes cellulaires à cause d'acides gras essentiels C20 et C22 diminués
US5444054A (en) * 1994-04-01 1995-08-22 Abbott Labatories Method of treating ulcerative colitis
EP0682879A1 (fr) * 1994-05-20 1995-11-22 HEIRLER, Horst Aliments diététiques avec acides gras à chaîne moyenne et leur application
EP0711503A2 (fr) * 1994-11-14 1996-05-15 Scotia Holdings Plc Lait fortifié avec GLA et/ou DGLA
WO1998048646A2 (fr) * 1997-05-01 1998-11-05 Beth Israel Deaconess Medical Center Inc. Formulation alimentaire contenant de l'acide arachidonique et procede d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ATTERBY H.: "An investigation into the effects of dietary fatty acids on intestinal activity.", FOOD SCIENCE & TECHNOLOGY TODAY, vol. 10, no. 3, - 1996, pages 159 - 163, XP000892706 *
BOEHM G. ; MULLER H.: "Docosahexanoic and arachidonic acid absorption in preterm infants fed LCP-free or LCP-supplemented formula", ANNALS OF NUTRITION AND METABOLISM, vol. 41, no. 4, - 1997, pages 235 - 241, XP000892643 *
CARNIELLI V.: "Intestinal absorption of long chain polyunsaturated fatty acids in preterm infants fed breast milk or formula", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 67, no. 1, - 1998, pages 97 - 103, XP000892641 *
MOYA M. ; JUSTE M.: "Intestinal absorption of LCPUFAs and plasma pattern in the preterm infant", PEDIATRIC RESEARCH, vol. 42, 1997, pages 409, XP000892678 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112509A3 (fr) * 2003-06-23 2006-08-03 Nestec Sa Formule nutritionnelle pour fonction de barriere intestinale optimale
US8394370B2 (en) 2003-06-23 2013-03-12 Nestec S.A. Nutritional formula for optimal gut barrier function
WO2004112509A2 (fr) * 2003-06-23 2004-12-29 Nestec S.A. Formule nutritionnelle pour fonction de barriere intestinale optimale
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
US7867485B2 (en) 2005-04-15 2011-01-11 Mead Johnson Nutrition Company Method for preventing or treating the development of respiratory allergies
US7867486B2 (en) 2005-04-15 2011-01-11 Mead Johnson Nutrition Company Method for preventing or treating the development of respiratory allergies
US7837989B2 (en) 2005-04-15 2010-11-23 Mead Johnson Nutrition Company Method for preventing or treating the development of respiratory allergies
US7923006B2 (en) 2005-04-15 2011-04-12 Mead Johnson Nutrition Company Method for preventing or treating the development of respiratory allergies
WO2006113034A1 (fr) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Utilisation de lactobacillus rhamnosus gg en combinaison avec un acide gras polyinsature a chaine longue pour traiter, prevenir ou attenuer une inflammation systemique chez un nourrisson nourri au lait maternise
US9844517B2 (en) 2010-12-29 2017-12-19 Abbott Laboratories Nutritional products including a novel fat system including fatty acids
EP3245875A3 (fr) * 2010-12-29 2018-02-14 Abbott Laboratories Produit alimentaire pour diminuer l'incidence de l'enterocolite necrosante chez un nourrisson, un tout-petit ou un enfant
EP3892101A3 (fr) * 2010-12-29 2022-06-29 Abbott Laboratories Procédés pour améliorer la tolérance, la digestion et l'absorption de nutriments solubles lipides chez un nourrisson, un tout-petit ou un enfant
WO2016050752A1 (fr) * 2014-09-30 2016-04-07 Nestec S.A. Composition nutritionnelle destinée à être utilisée pour activer la maturation et/ou la réparation des intestins et/ou du foie
RU2694195C2 (ru) * 2014-09-30 2019-07-09 Нестек С.А. Питательная композиция для применения при активации формирования и/или регенерации кишечника и/или печени

Also Published As

Publication number Publication date
EA200100662A1 (ru) 2001-12-24
CN1330542A (zh) 2002-01-09
BR9916156A (pt) 2001-09-04
HUP0104760A2 (hu) 2002-04-29
AR021669A1 (es) 2002-07-31
CA2351469A1 (fr) 2000-06-22
WO2000035443A9 (fr) 2000-12-07
AU3119600A (en) 2000-07-03
KR20020002361A (ko) 2002-01-09
NO20012947D0 (no) 2001-06-14
NO20012947L (no) 2001-06-14
EP1140063A1 (fr) 2001-10-10
JP2002532420A (ja) 2002-10-02
PL348810A1 (en) 2002-06-17
IL143322A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
Demmelmair et al. Lipids in human milk
Delplanque et al. Lipid quality in infant nutrition: current knowledge and future opportunities
KR100439166B1 (ko) 괴사성 소장 결장염의 발병률을 감소시키기 위한 조성물
CA2281706C (fr) Procede et compositions servant a limiter la frequence de l'enterocolite necrosante du nouveau-ne
JP5473330B2 (ja) ドコサヘキサエン酸およびルテインを含有する乳児用製剤
US11376222B2 (en) Lipid composition for improving body composition during catch-up growth
US20090054329A1 (en) Composition with docosapentaenoic acid
SA98190002B1 (ar) استخدام أحماض دهنية تحتوي على عدة روابط غير مشبعة polyunsaturated fatty acids لتقليل حدوث الالتهاب المعوي القولوني الناخر incidence of necrotizing enterocolitis
JP2009542227A (ja) 早期脳発達のための乳児用調乳
US5411751A (en) Reducing gastrointestinal irritation in infant nutrition
Sarkadi-Nagy et al. The influence of prematurity and long chain polyunsaturate supplementation in 4-week adjusted age baboon neonate brain and related tissues
CN110678086A (zh) 用于改善的饮食行为的婴儿配方物
CA3130026A1 (fr) Composition de matiere grasse et composition nutritionnelle basee sur celle-ci
EP1140063A1 (fr) Procede et composition pour l'entretien et la restitution de l'integrite de l'intestin
Berger et al. Nutritional implications of replacing bovine milk fat with vegetable oil in infant formulas
Gázquez et al. Docosahexaenoic acid supplementation during pregnancy as phospholipids did not improve the incorporation of this fatty acid into rat fetal brain compared with the triglyceride form
Spear et al. Milk and blood fatty acid composition during two lactations in the same woman
WO2004068969A1 (fr) Composition enterale pour la prevention et/ou le traitement d'une septicemie
Chao et al. Influence of dietary long‐chain PUFA on premature baboon lung FA and dipalmitoyl PC composition
MXPA01005978A (en) Method and composition for the maintenance and restitution of gut integrity
Wieland et al. Emulsification and fatty-acid chain length affect the utilization of medium-chain triglycerides by neonatal pigs
WO2023208925A1 (fr) Composition nutritionnelle destinée à être utilisée dans la prévention de l'obésité programmée chez des nourrissons de sexe féminin
CZ296899A3 (cs) Přípravky pro omezení výskytu nekrotizující enterokolitidy a způsob jejich výroby
NZ719159B2 (en) Lipid composition for improving body composition during catch-up growth
MXPA99007737A (en) Use of polyunsaturated fatty acids forreducing the incidence of necrotizing enterocolitis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814534.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2351469

Country of ref document: CA

Ref document number: 2351469

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 143322

Country of ref document: IL

Ref document number: 1999965234

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200104372

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 31196/00

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2000 587763

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005978

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020017007472

Country of ref document: KR

Ref document number: PV2001-2191

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 512750

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200100662

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999965234

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017007472

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999965234

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2001-2191

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020017007472

Country of ref document: KR